BDC-3042 is a proprietary agonist antibody that targets dectin-2, an immune-activating receptor expressed by tumor-associated macrophages (TAMs). This single-agent, dose-escalation Phase 1 clinical ...

Activating a protein called potassium channel Kv2.1 may help improve motor function in SMA, making it a potential SMA ...

Activating a protein called potassium channel Kv2.1 may help improve motor function in SMA, making it a potential SMA ...

A significant benefit was observed with Tysabri over Rebif in delaying SPMS disability progression when therapeutic lag was ...

Addenbrooke's Hospital has appointed a leading barrister to run an external inquiry into the surgeon's cases. | ITV News ...

Use of DYNE-101 is leading to improvements in muscle, and specifically finger, function in myotonic dystrophy type 1 patients ...

We recently published a list of the 12 Best Diagnostics Stocks to Invest In Right Now. In this article, we are going to take ...

The Goldman Sachs Group lowered shares of ICON Public (NASDAQ:ICLR – Free Report) from a buy rating to a neutral rating in a ...

We recently compiled a list of the Top 8 Trending AI Stock Updates On Wall Street Today. In this article, we are going to ...

Pliant Therapeutics has discontinued a pivotal Phase 2b/3 clinical trial evaluating bexotegrast as an IPF treatment.

Clinical research organisation (CRO) Icon has begun the integration of Medidata Clinical Data Studio into its clinical ...